Adding MYC/BCL2 double expression to NCCN-IPI may not improve prognostic value to an acceptable level.
Naree WarnnissornNonglak KanitsapPimjai NiparuckPaisarn BoonsakanPrapasri KulalertWasithep LimvorapitakLantarima BhoopatSupawee SaengboonChinnawut SuriyonplengsaengPichika ChantrathammachartTeeraya PuavilaiSuporn ChuncharuneePublished in: Blood research (2024)
Adding DE to the NCCN-IPI may not improve the prognostic value to an acceptable level in resource-limited settings. Multiple independent confirmatory studies from a large cohort of lymphoma registries have provided additional evidence for the clinical utility of DE.